Company Overview and News

 
Philip Morris, Procter & Gamble Plunge into Thursday’s 52-Week Low Club

4h 247wallst
April 19, 2018: Here are four stocks trading with heavy volume among 42 equities making new 52-week lows in Thursday’s session. On the NYSE decliners led advancers by about 2 to 1 and on the Nasdaq, decliners led advancers by about 9 to 5.
Upvote Downvote

 
Philip Morris stock set for worst day in 10 years - MarketWatch

5h marketwatch
Philip Morris International Inc.'s stock was on track for its worst percentage decline in a decade, dragging down other tobacco stocks as cigarette volumes dropped more than expected and the company's IQOS product experienced slower growth.
Upvote Downvote

 
Philip Morris Results Stoke Global Tobacco Stock Sell-Off - Bloomberg

8h bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Can Smokeless Unit Aid Altria (MO) This Earnings Season?

10h zacks
Altria Group, Inc. (MO - Free Report) is slated to release first-quarter 2018 results on Apr 26, before the opening bell. While Altria’s earnings surpassed the Zacks Consensus Estimate in the last quarter, it has a mixed record of earnings surprises over the trailing four quarters. We expect the company to gain from sturdy advancements in the smokeless products category, which will be reflected in the upcoming quarterly results.
Upvote Downvote

 
Consumer-staples stocks tumble, on track for worst session in two months - MarketWatch

11h marketwatch
Consumer-staples stocks sank on Thursday, putting it on track for its biggest decline in more than two months. The sector XLP, -2.55% lost 2.6%, its biggest one-day percentage drop since Feb. 5. By far, the biggest decliner in the sector was Philip Morris International Inc. PM, -14.06% which tumbled 13% after the tobacco giant reported quarter revenue that came in below expectations. According to FactSet, Thursday is poised to be the worst trading session in the history of Phillip Morris since being spun off from Altria Group Inc.
Upvote Downvote

 
Philip Morris Sales Disappoint as Cigarette Demand Dips More - Bloomberg

11h bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Can Altria’s 1Q18 Earnings Boost Its Stock Price?

2018-04-18 marketrealist
Altria Group (MO) is scheduled to announce its 1Q18 earnings before the market opens on April 26, 2018. As of April 17, 2018, Altria was trading at $63.97, which represents a fall of 9.1% since the announcement of its 4Q17 earnings on February 1, 2018.
Upvote Downvote

 
Tobacco Companies Might Be The Only Worthwhile Staples

2018-04-18 seekingalpha
Tobacco companies (among a few others) may be the only sub-sector with an attractive price/growth proposition.
Upvote Downvote

 
7 Sector ETFs to Own Now | InvestorPlace

2018-04-17 investorplace
I saw an article about sector exchange-traded funds recently. While the author was talking about the 11 different S&P 500 sectors and how you can trade each of them using State Street SPDRs, it got me wondering about all the other sector ETFs to own in the marketplace.
Upvote Downvote

1
Philip Morris (PM) Q1 Earnings: Can RRPs Pare Cigarette Woe?

2018-04-16 zacks
Philip Morris International Inc. (PM - Free Report) is slated to release first-quarter 2018 results on Apr 19, before the opening bell. The company’s earnings have lagged estimates in each of the past four quarters, with an average miss of 6.1%. Lately, Philip Morris has been treading on shaky grounds, thanks to the jolts from receding cigarette consumption stemming from strict government regulations and rising consumer awareness regarding the harmful impacts of tobacco.
Upvote Downvote

 
Top Trade Review

2018-04-16 seekingalpha
Our MO trade is "only" up 66% - on the way to 367% so still pretty fresh!
Upvote Downvote

 
Analog Devices: Total Return Is Good, Another Good Chip Business

2018-04-16 seekingalpha
Analog Devices total return outperformed the Dow average by 53.82% for my 51-month test period, which is great.
Upvote Downvote

10
Missed A Hot IPO? Subscriptions Soar Towards 5 Million At This Startup

2018-04-14 seekingalpha
We'll discuss an opportunity to dip your toes into the warming waters of a new entertainment technology company, growing like a weed.
Upvote Downvote

 
10 High-Dividend Stocks to Buy When the Market Is Blue

2018-04-13 investorplace
President Donald Trump ran on a ticket of making America great again. While the consensus on that point is very much split, what’s not deniable is the markets’ response. Trump’s pro-business agenda was credited with sparking an impressive rally. With enthusiasm overshooting rationality, however, high-dividend stocks are suddenly looking very attractive to investors.
Upvote Downvote

1
Dead Dividend Stocks Are Just Stocks To Sell

2018-04-13 seekingalpha
Simon Property Group (SPG) is still a buy. They have been a buy since summer of 2017. SPG is the best of the mall REIT operators. They have the best net operating margins on their properties and they have the best scale on their overhead expenses. Consequently, they are able to extract more value out of each property than any of their peers. On average, SPG's portfolio is very high quality. It is not quite as good as the portfolio for Taubman Centers (TCO) measured by sales per square foot, but they still have the best margins.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 02209S103